The infusion of ex-vivo expanded polyclonal FOXP3+ Tregs in patients with recently diagnosed T1D showed improved beta-cell function and reduced exogenous insulin requirement only short-term (39–41). Here, INS is linked to type 1 diabetes mellitus.